CJC-1295 + Ipamorelin is a USA-manufactured dual-peptide GH axis research blend combining CJC-1295 No DAC (ModGRF 1-29) — a synthetic GHRH analogue that activates the GHRH receptor on anterior pituitary somatotrophs via Gs-cAMP signaling — and Ipamorelin, a selective GH secretagogue that activates the ghrelin receptor (GHS-R1a) via the distinct Gq/11 intracellular pathway, providing simultaneous dual-receptor GH axis stimulation in a single research preparation.
The mechanistic rationale for the combination rests on the complementary and additive nature of GHRH receptor and ghrelin receptor activation — with research demonstrating that simultaneous engagement of both receptor pathways produces greater GH release than either compound alone, while Ipamorelin’s selectivity profile minimizes cortisol and prolactin co-secretion that can confound GH axis research outcomes. The blend enables investigation of physiologically patterned GH pulse dynamics in preclinical models without requiring separate administration of each compound.
Research has focused on this combination’s role in GH pulse generation, IGF-1 axis modulation, and the downstream anabolic and metabolic effects of dual-pathway GH stimulation — with comparative research designs using this blend alongside individual compounds such as CJC-1295 No DAC, Ipamorelin, and Tesamorelin allowing systematic dissection of GH axis pharmacology. For further reading see: Ipamorelin selective GH secretagogue research (PubMed).
Specifications:
- Purity: ≥99% (HPLC verified)
- Form: Lyophilized powder
- Storage: −20°C
For Research Use Only.
Reviews
There are no reviews yet.